# Ruxotemitide PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ruxotemitide

> The next catalyst for ruxotemitide, sponsored by Verrica Pharmaceuticals Inc. (VRCA), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for ruxotemitide?

The next catalyst for ruxotemitide, sponsored by Verrica Pharmaceuticals Inc. (VRCA), is its topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "- Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively -" [Calendar and source filings](https://sec-api.dev/pdufa/ruxotemitide)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-458527, https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/ruxotemitide#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ruxotemitide |
| Codes | VP-315, LTX-315 |
| Sponsor | Verrica Pharmaceuticals Inc. (VRCA) https://sec-api.dev/companies/vrca/catalysts |
| Indications | biopsy proven bcc |
| Modality | peptide |
| FDA designations | none disclosed |

## Timeline

### Apr 2022: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: biopsy proven BCC.
- First seen 2025-03-11, last confirmed 2025-03-11.
- SEC Form 10-K (accession 0000950170-25-037172): "In April 2022, we dosed the first patient in Part 1 of a three-part Phase 2, multicenter, open-label, dose-escalation proof-of-concept trial with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy in subjects with biopsy proven BCC." https://www.sec.gov/Archives/edgar/data/1660334/000095017025037172/vrca-20241231.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458527): "- Enrollment completed in the first of two pivotal trials in the global Phase 3 common warts program, with topline data for each trial expected in Q1 2027 and mid-2027, respectively -" https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458527): "Topline data readouts for the trials are expected in the first quarter of 2027 and mid-2027, respectively." https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458527): "We have also enrolled more than 50% of the current patient target in the second pivotal trial, and we expect topline data from these trials in the first quarter of 2027 and mid-2027, respectively." https://www.sec.gov/Archives/edgar/data/1660334/000119312526458527/d144356dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ruxotemitide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ruxotemitide PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ruxotemitide

```bibtex
@misc{secapidev_pdufa_ruxotemitide_20261116,
  title        = {Ruxotemitide PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ruxotemitide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ruxotemitide_20261116","title":"Ruxotemitide PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ruxotemitide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
